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ABSTRACT 
 
Protein misfolding and aggregation is an unwanted phenomenon occurring in cells  which is one of 
the cause of various degenerative diseases. The conformational changes occurring due to certain 
environmental conditions and due to the mutations in the native state causes large amount of β 
sheets which are stable in the body environment because of their lower energy state. Once amyloid 
formation takes place lysis of these molecules becomes really difficult. Hence it is very important 
to stop aggregation at its very early stage. 
In this work modification was done on existing protocols on protein aggregation and an altogether 
new protocol was developed .Using this protocol, which involved denaturing of lysozyme protein 
at high temperatures, interference of molecules like oleic acid and sucrose were observed on the 
aggregates formed. Thioflavin T assay and Congo red assay were performed .Observations were 
monitored and recorded using fluorescence spectrophotometer and UV/VIS spectrophotometer.  
Oleic acid was found to accelerate the aggregation mechanism whereas sucrose was found to 
inhibit it. This important analysis gave important information about molecules that can be 
administered as drugs for inhibiting protein aggregation. 
 
Key words: Protein mis-folding, protein aggregation, spectrophotometer. 
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INTRODUCTION 
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   1.1.   INTRODUCTION: 
A polypeptide chain consisting of basic amino acids joined by a peptide bond forms the primary 
structure. Within the long protein chains there are regions in which the chains are organised into 
regular structures known as alpha-helices (alpha-helixes) and beta-pleated sheets. These are the 
secondary structures in proteins. These secondary structures are held together by hydrogen bonds. 
The tertiary structure of a protein is a description of the way the whole chain (including the 
secondary structures) folds itself into its final 3-dimensional shape. Proteins are folded and held 
together by several forms of molecular interactions. The molecular interactions include the 
thermodynamic stability of the complex, the hydrophobic interactions and the disulphide bonds 
formed in the proteins. The biggest factor in a proteins ability to fold is the thermodynamics of the 
structure. The interaction scheme includes the short-range propensity to form extended 
conformations, residue-dependent long-range contact potentials, and orientation-dependent 
hydrogen bonds. 
 
The thermodynamics are a main stabilizing force within a protein because if it is not in the lowest 
energy conformation it will continue to move and adjust until it finds its most stable state. The next 
type of interaction in protein folding is the hydrophobic interactions within the protein (Acharya 
and Taniuchi, 1982). The thermodynamics play an important role in secondary structure formations 
while hydrophobic hydrophobic interactions affect the tertiary structure mainly (Arakawa and 
Tsumoto, 2003). These hydrophobic interactions also have an impact on the primary structure. 
 
Globular proteins acquire distinct compact native conformations in water as a result of the 
hydrophobic effect. Hydrophobic cores are generally present in correctly folded state which are the 
basis of channel formation within the cell (Arakawa and Tsumoto, 2003). The hydrophobic 
interactions are shown to have an impact on the protein even after it has found the most stable 
conformation in how the proteins can interact with each other as well as folding themselves 
(Tsumoto et al., 2004). 
 
Disaggregation of proteins is caused by a special class of molecules called the HSP (Heat Shock 
Proteins). Protein misfolding is a common property among proteins and is dependent upon various 
conditions. The main amino acid sequence and certain mutations accelerate the process. Moreover, 
it also depends on environmental conditions, because once proteins are exposed to specific 
environmental changes such as increased temperature, high or low pH, agitation, elevated glucose, 
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or oxidative agents, they can lose their native conformation more rapidly. The loss of the native 
state of the proteins causes their denaturation and leads to unfolding. Because of the lack of 
arrangement, unfolded proteins are non-functional as they have lost the 3 dimensional tertiary 
structure which defines their function (Ventura and Villaverde, 2006). 
 
Importantly, the unfolded state is thermodynamically unfavourable and unstable. Seeking lower 
energy levels and more stability, unfolded proteins have a tendency to aggregate and attain a state 
of lowest energy level and become thermodynamically stable. During aggregation, proteins change 
dynamically and most of the alpha helical structures change into cross-β structure, including 
intermediates varying from unordered amorphous aggregates to ordered fibrils that are called 
amyloid (Tsumoto et al., 2004). Subsequent to protein misfolding, aggregation, which consists of 
two parts, starts. Nucleation is the first part, when proteins reversibly attaches to a growing 
hydrophobic core. The second part is when other protein molecules attach themselves to this core. 
The formation of large number of β-sheet and high concentration makes the aggregate highly 
stable. Low net charge also is one of the important initiators of protein aggregation because it 
provides stability and lower energy state. Depending on the protein, there are various alternatives 
concerning how the precursor of aggregation is generated from native proteins. Incomplete protein 
degradation and introduction of any misfolding variant is the main reason of development of a 
precursor (Tsumoto et al., 2004).    
 
1.2. Various models on protein aggregation: 
1.2.1.   Lumry – Eyring Two State Model: 
This is a model for protein aggregation. According to this model, the native protein undergoes first 
a reversible conformational change to an aggregation prone state, which subsequently assembles 
irreversibly to the aggregated state (Ma et al., 2003).  
1.2.2.   Polymerization model: 
In this model, misfolding occurs as a consequence of protein aggregation which follows a 
crystallization-like process dependent upon nucleus formation. The nucleus that is formed is the 
base of aggregation formation (Soto, 2001). 
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1.2.3.   Conformational model: 
This model proposes that induced conformational changes results in the formation of the 
misfolded protein caused due to mutation of the native state that may or may not aggregate. 
Amyloid formation is not a mandatory step in this model (Soto, 2001). 
1.2.4.   Oligomerization model: 
Intermediate formation takes place due to slight conformational change. This intermediate is 
unstable due to the presence of hydrophobic chores and high energy state. The formation of β 
sheets by interaction with other such intermediates stabilizes this state, which by further growth 
produces amyloids (Soto, 2001).  
 
1.3.   A summary of methods used for analysis of protein aggregates: 
Table 1. Methods used for analysis of protein aggregates 
Method Application 
SDS – PAGE 
SE-HLPC 
RP-HLPC 
Size estimation and to distinguish from 
reducible covalent from non – covalent 
aggregates (Singh et al., 1991). 
 Capillary Electrophoresis 
Field Flow Fraction 
 
Size estimation and quantification (Chien, 
1991) 
Static Light Scattering Size and shape estimation (Brown, 1996) 
Dynamic Light Scattering Size distribution (Goldburg, 1999) 
Analytical Ultracentrifugation Size, shape estimation and quantification 
(Laue, 2001) 
Coulter Counter Size and member estimation (Bull et al., 
1965) 
CD 
Fluorescence Spectroscopy 
IR Spectroscopy 
NMR Resonance 
 
Structural Analysis (Vliegenthart et al., 
1983) 
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  1.4.   OBJECTIVES: 
 To modify existing protocols and to develop an altogether novel protocol for lysozyme    
aggregation. 
 To investigate the effect of artificial chaperones on the aggregates formed. 
. 
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2.1. Hen egg white lysozyme : 
Lysozyme is present in the mucosal secretion such as saliva and tears. In high concentration, about 
3% from all proteins, Lysozyme is present in chicken egg-white. This enzyme is only effective 
against Gram positive bacterial cells. Gram negative bacteria and yeast are completely resistant to 
lysing by it. Molecular weight – 14307 Da and its isolectric point – 11.35 and optimum pH – 6-9 
(maximum activity at 6.2) (Blake et al., 1967). 
 
2.2.1.   Substrates
 
and inhibitors: 
The natural substrate for lysozyme is the peptidoglycan layer of bacterial cell walls. However, to 
make various photometric, isotopic, and immunological lysozyme assays ,variety of low molecular 
mass substrates including murine degradation products as well as synthetic compounds have been 
used  (Lee and Timasheff, 1981). 
 
2.2.2.   Compounds that affect protein aggregation: 
Acridine derivatives, kaempferol, curcumin, surfactant coplymers like Polyethylene Oxide – 
Polypropylene Oxide – Polyethylene Oxide (PEO – PPO – PEO) inhibit aggregation while steel, 
glass, silicon rubber accelerate aggregation (Arakawa and Tsumoto, 2003). 
. 
2.3.    Artificial chaperones and their role in protein refolding: 
Denaturation of tissue proteins following exposure to high temperatures or other various stresses is 
thought to be a major cause of tissue death. Thermo tolerance can be induced in biological cells 
(Kudou et al., 2003) . The molecular mechanism of this thermo tolerance involves increased 
biosynthesis of heat shock proteins that is the chaperone refolding of heat denatured proteins. The 
induction of heat shock proteins indicate that with the increase in concentration of chaperones the 
damage done to cells can be reversed. For burn and similar state injuries synthetic chaperones can 
be induced that play the role of natural chaperones and cause protein folding. In situations when 
normal cellular repair functions are incapable of managing the injury caused by heat, the 
availability of techniques to repair this damage is limited in the pharmaceutical industry. 
Therefore, for the treatment of such trauma and injuries there arises and inevitable need of creating 
synthetic molecular chaperones. It is well established that several human shock proteins can 
catalyse solubilisation and refolding of stable misfolded protein aggregates. The mechanism of 
refolding by human shock proteins is that they bind to the unfolded proteins to prevent or reduce  
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 The self-association of denatured proteins and prevent aggregation. In principle, unfolded proteins 
may spontaneously refold to their native states, or intermediate states, if their aggregation is 
prevented and this is targeted as the base trauma therapeutics (Krause et al., 2002). 
 2.4.   Small molecule inhibitors of lysozyme aggregation: 
Protein aggregation is associated with a number of degenerative human pathologies, but the   
precise mechanisms underlying the toxicity of amyloids and their cure is still under proper study. 
They are still incompletely understood. In this context, drugs capable in blockade of  the 
aggregation and misfolding of amyloid genic proteins should be considered in strategies aimed at 
the development of novel therapeutic drugs (Kita et al., 1994). Human lysozyme variants have 
been shown to form massive amyloid deposits in the livers and kidneys of individuals affected by 
hereditary systems (systemic amyloidosis) (Arakawa and Tsumoto, 2003).Various studies clearly 
show that these small molecules can act as prototypes for the development of drugs against 
amyloidosis.  
2.5.   Inhibition of amyloid fibrillation of lysozyme by indole derivatives: 
Amyloid deposits are associated with chronic neuronal and systemic pathologies, including 
Alzheimer’s, Parkinson’s and Huntington’s diseases, transmissible spongiform encephalopathy, 
and type II diabetes. Whole proteins and protein fragments that form the amyloid structures have 
have very minute fibrilar shape, formed of a network of cross β-sheet structure, which is the result 
of a conformational change of the native protein structure. These proteins have a domain from 
small peptides (e.g. amyloid b-peptide, amylin and insulin), to natively unfolded proteins (e.g. a-
synuclein) and natively folded monomeric proteins (e.g. lysozyme), or even protein assemblies 
(e.g. transthyretin). As there is no sequence similarity between these proteins that have large 
structural diversity, it has been suggested that amyloid formation may be a generic property of 
polypeptide chains. On the basis of this phenomenon efforts have been devoted to obtaining a 
better understanding of amyloids formation mechanisms and, in parallel, finding methods for 
intervention. 
Common inhibitors may be present for various amyloids which is inferred from their common 
features. Accordingly,  some reports suggest that there can be some inhibitory effects of small 
organic compounds on fibril formation by different proteins. Some of these inhibitors have been 
observed to affect conversion to oligomeric intermediates, which are considered to be the most 
harmful forms of these proteins for living cells. These small inhibitors can also disaggregate 
previously formed filaments of various proteins. Moreover, they may also stabilize the native form 
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of aggregation oriented proteins by favouring the transformation kinetics towards native stable 
oligomeric states, and may possess antioxidant properties, thereby counter affecting the toxic 
effects of active oxidants which play a crucial role in aggregation. Usually, these molecules are 
effective at very low concentrations, and some, such as indole derivatives, are currently used in 
other related conditions, making them interesting leading structure candidates in amyloid-linked 
diseases. 
There are still many uncertain points with regards to the detailed mechanisms of action of these 
compounds and the conditions under which they are functional against aggregation. Because   
protein fibrillation is entirely dependent on its sequence, and since hydrophobic and stackable 
residues participate mainly in the early stages of this process, it has been suggested that disruption 
of hydrophobic and ð-stacking interactions of aromatic residues may be involved which can lead 
to reduced aggregation. Indole derivatives can bind to proteins, but the nature of the derivative is 
very important in this regard. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
` 
11 
 
 
 
 
 
 
CHAPTER 3 
MATERIALS 
AND METHODS 
 
 
 
 
 
 
 
 
` 
12 
 
3.1. Chemicals used: 
Lysozyme (RM074-1G), Dibasic Sodium Phosphate: - NaH2PO4 (RM6382 -550G), Guanidine 
hydrogen chloride (MB-014-500G), Thioflavin T (RM-10365), Congo red (RM-500G) purchased 
from HIMEDIA pvt ltd. Monobasic Sodium Phosphate: - Na2HPO4 (61754905001730) purchased 
from MERCK pvt ltd. 
 
3.2. Equipment used: 
Fluorescence spectrometer (Perkin Elmer LS55) and UV/Visible spectrophotometer (Perkin Elmer 
λ-35) were used to monitor and record all the results obtained. 
 
3.3. Method: 
3.3.1. Preparation buffer  stock: 
A buffer stock was prepared which was used to maintain the pH.  For preparation of 50 ml of .1 M 
sodium phosphate buffer 2.89 ml of 1 M sodium dihydrogen phosphate was taken and 2.12 ml of 
sodium monohydrogen phosphate was taken and then the volume was adjusted to 50 ml (Ho et al., 
2003). 
 
3.3.2. Preparation of stock Lysozyme  solution: 
          1 mg/ml stock solution of lysozyme was prepared. For this 2 mg of lysozyme was taken and 1 ml 
of 100 µM of sodium phosphate buffer was added. 
 
3.3.3. Tested Protocols used for Lysozyme aggregation: 
3.3.2.1. Protocol 1: 
The stock buffer solution was adjusted to 20 μM adjusting its pH to 6.3. To 10 μM solution of 
lysozyme 3 M guanidine hydrochloride solution was added. The solution  was stirred using a 
magnetic stirrer at 60 rpm for 20 mins (Hevehan and De Bernardez Clark, 1997). 
3.3.2.2. Protocol 2: 
A solution containing 1mg/mL lysozyme and 50 mM sodium phosphate Buffer was                   
prepared and the pH was adjusted to 7.16. 200 μL aliquot of the stock solution was taken in a 
microtube and was then placed in a water bath. Temperature was increased from 25°C to 90°C at 
1°C /sec. It was stored at 25°C for 20 mins. It was then centrifuged at 15000 g for 20 mins at 25
o
C. 
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3.3.2.3. A complete novel protocol for aggregation: 
A stock solution of 1mg/mL lysozyme was prepared in 50 mM sodium phosphate buffer and the 
pH was adjusted to 7.16. From lysozyme (1mg/ml) stock solution 200 μL was added to 1 mL of 
buffer  It was then heated at 100°C for 20 mins in a water bath. It was incubated at 25°C for 20 
more mins after heating (Goldberg et al., 1991). 
 
3.3.4. Protocol used for studying the effect of oleic acid and sucrose on Lysozyme 
aggregation: 
Two test tubes were taken and were marked “Before Boiling” and “After Boiling”.  1mL of 
1mg/mL lysozyme stock solution was taken in both test tubes. 100 μL of oleic acid   having 
volume fraction= 1 was added to the test tube marked “Before Boiling”.   Both the test tubes were 
closed using cotton plugs and aluminium foil. They were kept in the water bath for 20 mins at 
100°C. After heating, both the test tubes were stored for 20 more mins at room temperature to 
allow the oleic acid to act properly on the aggregates formed in the test tube marked “Before 
Boiling” and “After boiling” (De Bernardez Clark et al., 1999). 
 
3.3.5.  Thioflavin T assay: 
     In four test tubes markings were done: “C” (Control Solution), “A” (Aggregated Solution), “BB1” 
(Addition of reagent before boiling), and “AB1” (Addition of reagent after boiling). The test tubes 
were incubated in the dark. Test tube “C” 100 μL of contained native lysozyme, 2885 μL of 
sodium phosphate buffer and 15 μL of Thioflavin T dye. Test tube “A” contained 100μL 
aggregated solution, 2885μL of sodium phosphate buffer and 15 μL of Thioflavin T. Test tube 
AB1 contained 100 μL of Sucrose or Oleic Acid, 100 μL of aggregated lysozyme solution, 2785 
μL of sodium phosphate buffer and 15 μL of Thioflavin T dye. Test tube BB1 contained 200 μL of 
solution containing Sucrose or Oleic Acid and the aggregated solution of Lysozyme, 2785 μl of 
sodium phosphate buffer and 15 μL of Thioflavin T dye (Brinkmann et al., 1992). 
 
3.3.6.  Congo Red assay: 
In five test tubes the following markings were done: “CR” (Congo Red), “C” (Control        
Solution), “A” (Aggregated Solution), “BB1” (Addition of reagent before boiling), and “AB1” 
(Addition of reagent after boiling) .Incubation was done in the dark. In four test tubes markings 
were done: “C” (Control Solution), “A” (Aggregated Solution), “BB1” (Addition of reagent before 
boiling), and “AB1” (Addition of reagent after boiling). The test tubes were incubated in the dark. 
` 
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Test tube “C” 100 μL of contained native lysozyme, 2885 μL of sodium phosphate buffer and 
15μL of CR dye. Test tube “A” contained 100μL aggregated solution, 2885 μL of sodium 
phosphate buffer and 15 μL of CR. Test tube AB1 contained 100 μL of Sucrose or Oleic Acid, 100 
μL of aggregated lysozyme solution, 2785 μL of sodium phosphate buffer and 15 μL of congo red 
dye. Test tube BB1 contained 200 μL of solution containing Sucrose or Oleic Acid and the 
aggregated solution of Lysozyme, 2785 μL of sodium phosphate buffer and 15 μL of CR dye. Test 
tube “CR” contained pure congo red solution of 15 μL and 2985 μL of sodium phosphate buffer 
(Asano et al., 2002). 
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4.1.   Thioflavin T assay on lysozyme aggregation by protocol 1: 
The graph below shows that lysozyme aggregate solution at 0 h had the lowest peak. The 
discrepancy is that the peak of the control solution was found to be greater than that of the test 
solution at 0 h which completely contradicts the theory which says that the control solution should 
have the lowest peak value. This may be attributed to the presence of guanidine hydrochloride 
solution. Hence this protocol did not give the desired results. 
 
 
 
Figure 1. Graph depicting results of Thioflavin T assay performed on lysozyme aggregates 
formed by Protocol 1. (1) Lysozyme aggregate solution observed after 24 h. (2) Native lysozyme 
solution. (3) Lysozyme aggregate solution observed after 15 h. (4) Lysozyme aggregate solution 
observed after 0 h.  
. 
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4.2.   Thioflavin T assay on lysozyme aggregation by protocol 2: 
The graph below shows that the aggregation is less in the test solution (aggregated lysozyme 
solution) than in the control solution, which is absurd considering that control solution itself 
contains “non-aggregated” lysozyme. It can be inferred that the process of increasing the 
temperature from 25°C to 90°C gradually may not have supported the proper denaturation of 
lysozyme. 
 
 
 
 
Figure 2.  Graph depicting results of Thioflavin T assay performed on lysozyme aggregates 
formed by Protocol 2. (1) Native lysozyme Solution. (2) Aggregated lysozyme Solution. 
 
. 
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4.3. Congo red ssay on lysozyme aggregation by protocol 2: 
No peaks were observed for control and test solutions in the Congo Red assay, although a peak    
was observed for the Congo Red solution. This indicated nothing about the formation of 
aggregates or amyloid formation. No peak formation in this case when compared to Thiflavin T 
assay results may be attributed to the less sensitivity of  Congo Red. 
                                  
 
 
Figure 3. Graph depicting results of Cong Red assay performed on lysozyme aggregates formed 
by Protocol 2. (1) Pure Congo Red Solution.(2) Native lysozyme Solution.(3) Aggregated 
lysozyme Solution. 
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4.4.   Thioflavin T assay on lysozyme aggregation by protocol 3: 
The graph below shows that the appearance of peak clearly shows the formation of aggregation. 
This may be caused due to the denaturing of the protein when heated to 100°C  which causes the 
hydrophobic chores to be exposed and leads to hydrophobic-hydrophobic interactions within the 
molecule. Hence aggregation takes place.        
 
 
  
Figure 4.  Graph depicting results of Thioflavin T assay performed on lysozyme aggregates 
formed by Protocol 3 (Novel protocol). (1) Aggregated lysozyme Solution. (2) Native lysozyme 
Solution.  
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4.5.  Congo Red Assay on lysozyme aggregation by protocol 3: 
Results from Congo Red assay indicated that there is no amyloid formation as no shift in peak was 
observed. This protocol was dubbed as accurate and perfect for lysozyme aggregation under the 
laboratory conditions. 
 
 
Figure 5.  Graph depicting results of Congo red assay performed on lysozyme aggregate formed 
by Protocol 3. (1) Aggregated lysozyme Solution. (2) Native lysozyme Solution. (3) Pure Congo 
Red Solution. 
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4.6 Thioflavin T Assay showing the effect of oleic acid on lysozyme  
aggregation: 
As observed from the Thioflavin T assay, oleic acid significantly increased the aggregation in 
lysozyme, both when added before and after boiling. Oleic acid causes agitation by binding at sites 
favouring more hydrophobic hydrophobic interactions hence favours the denatured state more and 
causes acceleration in the process of lysozyme aggregation. 
 
Figure 6.  Graph depicting results of Thioflavin T assasy performed on aggregated lysozyme and 
oleic acid solution. (1) Aggregated lysozyme and oleic acid solution after boiling. (2) Aggregated 
lysozyme and oleic acid solution before boiling. (3) Aggregated lysozyme solution. (4) Native 
lysozyme solution. (5) Sodium Phosphate Buffer solution. 
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4.7 .  Thioflavin T Assay showing the effect of sucrose on lysozyme aggregation: 
The graph below shows that, sucrose significantly decreased the aggregation in lysozyme, both 
when added before and after boiling. This, again follows a simple mechanism. Poly solvents like 
sucrose increase the thermal stability of lysozyme and proteins in general. 
Figure 7.  Graph depicting results of Thioflavin T assay performed on aggregated lysozyme and 
sucrose solution. (1) Aggregated lysozyme solution. (2) Aggregated lysozyme and sucrose 
solution before boiling. (3) Aggregated lysozyme and sucrose solution after boiling. (4) Native 
lysozyme solution. (5) Sodium Phosphate Buffer solution. 
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4.8.  Congo red  Assay showing the effect of sucrose on lysozyme aggregation: 
 
Again, no major peak shifts were observed in the Congo Red assay indicating that there was no 
amyloid formation in the solution. 
 
 Figure 8.  Graph depicting results of  Congo Red assay performed on aggregated lysozyme and 
sucrose solution. (1) Aggregated lysozyme Solution (2) Aggregated lysozyme and sucrose solution 
before boiling (3) Aggregated lysozyme solution and sucrose before boiling. 
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CHAPTER 5 
CONCLUSION 
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5.1.  Conclusion: 
With the use of congo red assay and Thioflavin T assay the aggregation of lysozyme was studied. 
At 100°C the aggregation was found to be immense. Sucrose was observed to be an inhibitor of 
aggregation of lysozyme. The reason of reduced aggregation can be related to the fact that sucrose 
caused less hydrophobic - hydrophobic interaction by binding to the core and thus favouring the 
native state over its denatured state. The energy of the native state is decreased and stability is 
increased. Oleic acid accelerated the process of aggregation both before and after boiling. Oleic 
acid being hydrophobic itself supports hydrophobic interactions within the protein molecule when 
its starts to denature due to heating. Lysozyme assembles into multimeric complexes in a solution 
with oleic acid which can also be considered as a reason for the increased aggregation observed.  
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